Literature DB >> 18317008

4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues.

Carl R Alving.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317008     DOI： 10.1097/QAD.0b013e3282f51922

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  11 in total

1.  Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Authors:  Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

Review 2.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

3.  Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody.

Authors:  Edurne Rujas; José M M Caaveiro; Sara Insausti; Miguel García-Porras; Kouhei Tsumoto; José L Nieva
Journal:  J Biol Chem       Date:  2017-02-17       Impact factor: 5.157

4.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

5.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

6.  Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions.

Authors:  Ramesh Rathinakumar; Moumita Dutta; Ping Zhu; Welkin E Johnson; Kenneth H Roux
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

7.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.

Authors:  Erin M Scherer; Daniel P Leaman; Michael B Zwick; Andrew J McMichael; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

8.  Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization.

Authors:  Beatriz Apellániz; Edurne Rujas; Pablo Carravilla; José Requejo-Isidro; Nerea Huarte; Carmen Domene; José L Nieva
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.

Authors:  Ema T Crooks; Tommy Tong; Bimal Chakrabarti; Kristin Narayan; Ivelin S Georgiev; Sergey Menis; Xiaoxing Huang; Daniel Kulp; Keiko Osawa; Janelle Muranaka; Guillaume Stewart-Jones; Joanne Destefano; Sijy O'Dell; Celia LaBranche; James E Robinson; David C Montefiori; Krisha McKee; Sean X Du; Nicole Doria-Rose; Peter D Kwong; John R Mascola; Ping Zhu; William R Schief; Richard T Wyatt; Robert G Whalen; James M Binley
Journal:  PLoS Pathog       Date:  2015-05-29       Impact factor: 6.823

10.  Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.

Authors:  Nerea Huarte; Aitziber Araujo; Rocio Arranz; Maier Lorizate; Heribert Quendler; Renate Kunert; José M Valpuesta; José L Nieva
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.